Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Recombinant DNA01:09

Recombinant DNA

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of higher versus lower PEEP on mortality in mechanically ventilated patients with Sepsis - A multicenter, multi-cohort observational analysis.

Journal of critical care·2026
Same author

Phosphorylated toll-like receptor 4 defines a high-risk sepsis endotype.

Critical care (London, England)·2026
Same author

Individualized anticoagulation monitoring in critically ill patients: study protocol for a prospective observational comparison of Anti-Xa, viscoelastic testing, and thrombin generation.

Frontiers in medicine·2026
Same author

Comparing Hemostatic Efficacy of Four-factor Prothrombin Complex Concentrate with Andexanet Alfa in an Apixaban-treated Polytrauma Male Porcine Model.

Anesthesiology·2026
Same author

The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock.

Annals of intensive care·2026
Same author

Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activity.

BMC anesthesiology·2026
Same journal

Reimagining cardiac surgery-the emerging role of prehabilitation and risk optimization.

Best practice & research. Clinical anaesthesiology·2026
Same journal

Prehabilitation and enhanced recovery after cardiac surgery.

Best practice & research. Clinical anaesthesiology·2026
Same journal

The role of biomarkers in the preoperative evaluation of cardiac surgical patients - A narrative review.

Best practice & research. Clinical anaesthesiology·2026
Same journal

Magic in a bottle? A Focused review of factor concentrates for the intraoperative treatment of acquired coagulopathy - Fibrinogen concentrate, prothrombin complex concentrate, and recombinant activated factor VII.

Best practice & research. Clinical anaesthesiology·2025
Same journal

ESAs in perioperative anemia management: Who, what, how and why?

Best practice & research. Clinical anaesthesiology·2025
Same journal

Does patient blood management represent good value for money?

Best practice & research. Clinical anaesthesiology·2025
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Activated recombinant factor VII (rFVIIa).

Oliver Grottke1, Dietrich Henzler, Rolf Rossaint

  • 1Department of Anaesthesiology, Institute for Laboratory Animal Science, RWTH Aachen University Hospital, Pauwelsstrasse 30, D-52074 Aachen, Germany. ogrottke@ukaachen.de

Best Practice & Research. Clinical Anaesthesiology
|April 21, 2010
PubMed
Summary
This summary is machine-generated.

Recombinant activated factor VII (rFVIIa) is a hemostatic agent used for bleeding. This review examines its efficacy and safety in the perioperative period, considering existing evidence and potential biases.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Area of Science:

  • Hematology
  • Pharmacology
  • Surgical Hemostasis

Background:

  • Recombinant activated factor VII (rFVIIa) is a hemostatic agent initially developed for hemophilia patients with inhibitors.
  • Its use has expanded to various life-threatening bleeding conditions, often as a last resort.
  • Growing case reports suggest efficacy, but conflicting results necessitate a review of evidence.

Purpose of the Study:

  • To summarize the clinical evidence regarding the efficacy of rFVIIa in the perioperative period.
  • To evaluate the safety profile of rFVIIa in surgical bleeding scenarios.
  • To address the limitations of existing data, including potential publication bias.

Main Methods:

  • Systematic review of clinical studies and case reports on rFVIIa use in perioperative bleeding.
  • Analysis of efficacy data in controlling or preventing hemorrhage.
  • Assessment of reported adverse events and safety concerns.

Main Results:

  • rFVIIa has demonstrated potential in managing severe perioperative bleeding across diverse clinical settings.
  • Evidence is largely derived from case reports and series, with limited randomized controlled trials.
  • Conflicting outcomes and safety data highlight the need for further rigorous investigation.

Conclusions:

  • rFVIIa shows promise as an adjunct for perioperative hemostasis in life-threatening bleeding.
  • Further high-quality research is essential to establish definitive efficacy and safety profiles.
  • Careful consideration of available evidence is crucial for its judicious use in clinical practice.